What these criteria are for
The 2016 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) classification criteria for primary Sjögren's syndrome (pSS) provide a standardized, weighted definition intended mainly for research, registries, and clinical trials. They help ensure that cohorts labeled as pSS are comparable across centers and studies. Like other ACR/EULAR classification instruments, they support clinical reasoning but are not a substitute for individualized diagnostic judgment, especially when presentation is atypical, data are incomplete, or overlapping conditions must be considered.
Conceptual design: symptoms plus objective weighted findings
The framework has three logical layers. First, the criteria apply only to people who meet inclusion (they have a relevant symptom pattern or trial-based suspicion of Sjögren's). Second, specific exclusion diagnoses remove patients from this classification scheme because they can mimic sicca, interfere with testing, or confound interpretation. Third, among those who remain eligible, points are assigned for a small set of objective immunologic, histopathologic, and glandular measures. The points are summed; a total of 4 or more (out of a maximum of 9) fulfills the 2016 ACR/EULAR classification definition of pSS, provided inclusion is satisfied and exclusions are absent.
This design deliberately emphasizes objective evidence of immune-mediated exocrinopathy and characteristic autoimmunity (notably anti-SSA/Ro) rather than relying on symptom checklists alone. That improves specificity for studies while still requiring a sensible pretest context (inclusion) so the tool is not applied indiscriminately.
Inclusion criteria (who the score applies to)
Classification is meant for individuals with at least one of the following entry conditions:
- Symptomatic ocular or oral dryness as defined by a positive answer to at least one of the consensus symptom questions, including (paraphrased for clinical use) daily, persistent, troublesome dry eyes for more than three months; a recurrent gritty or "sand or gravel" sensation in the eyes; use of tear substitutes more than three times per day; a daily feeling of dry mouth for more than three months; or frequently drinking liquids to help swallow dry food.
- Suspicion of Sjögren's from systemic activity profiling using the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI), specifically when there is at least one domain with a positive item, reflecting how the criteria were operationalized for trial and cohort entry in the consensus process.
Clinicians and investigators should document which inclusion pathway applies, because applying the weighted score outside these contexts reduces meaningfulness: the instrument assumes you are already evaluating someone in whom pSS is a reasonable consideration.
Exclusion criteria (who must not be classified as pSS under this system)
A prior diagnosis of any of the following conditions excludes classification as pSS under this scheme (and, in the original framework, participation in certain SS studies where overlap would distort case definition):
- History of head and neck radiation (can cause severe glandular dysfunction unrelated to autoimmune pSS).
- Active hepatitis C infection with positive PCR (associated with sicca, cryoglobulinemic features, and serologic patterns that overlap with SS phenotypes).
- HIV/AIDS (immunologic and glandular manifestations can overlap).
- Sarcoidosis (can involve lacrimal glands and mimic sicca syndromes).
- Amyloidosis (infiltrative gland disease and systemic features may overlap).
- Graft-versus-host disease (chronic GVHD is a major mimic of sicca and salivary involvement).
- IgG4-related disease (can involve salivary glands and create inflammatory gland disease that is distinct from classic pSS pathophysiology and histology).
These exclusions are not a comment on whether a patient "has dryness"; they reflect the need for a homogeneous case definition when the label pSS is used for research. In bedside diagnosis, overlap syndromes still require expert synthesis, but the classification score should not be reported as fulfilled pSS when an exclusion diagnosis is present per the published rules.
Weighted items and how they map to pathophysiology
Each item below is scored only if present, using the specified methods and thresholds. The three ocular and oral secretory function items are each worth 1 point; the two "anchor" items (characteristic autoantibody and characteristic histology) are each worth 3 points, reflecting their stronger discriminative value in the consensus data-driven modeling.
1. Labial salivary gland biopsy: focal lymphocytic sialadenitis (3 points)
Minor salivary gland biopsy remains a cornerstone objective test in difficult cases. The criterion requires focal lymphocytic sialadenitis with a focus score of at least 1 focus per 4 mm² of glandular tissue. Foci are aggregates of ≥50 lymphocytes (per the referenced histopathology standards used in the criteria development). The biopsy should be interpreted by a pathologist with appropriate expertise, using a standardized approach to focus counting; technical quality (adequate tissue, correct orientation) materially affects validity.
Biopsy is particularly useful when serology is negative or conflicting, or when another diagnosis (for example, non-specific chronic sialadenitis) must be excluded. It is invasive, so it is not required for every clinical encounter, but for classification it is a high-weight item when positive.
2. Anti-SSA (Ro) antibody positivity (3 points)
Anti-SSA/Ro antibodies are strongly associated with autoimmune exocrinopathy and extraglandular features in Sjögren's spectrum disease. The criterion uses laboratory-defined positivity according to the assay used. Because platforms differ (ELISA, chemiluminescence, addressable laser bead immunoassays, etc.), local validation and clinical laboratory cutoffs matter; borderline or weak results should be interpreted cautiously and, when feasible, corroborated with consistent clinical and objective findings.
This item captures a major serologic "anchor" for immune-mediated disease in the same way biopsy captures tissue-level confirmation.
3. Ocular surface staining: OSS ≥5 or van Bijsterveld ≥4 in at least one eye (1 point)
Ocular staining scores quantify ocular surface epithelial damage attributable to tear film instability and inflammation. The criterion allows either a defined ocular staining score (OSS) threshold or the classic van Bijsterveld score alternative, measured in at least one eye using the standardized grading approaches referenced in the original publication.
Practical issues include inter-rater training, use of consistent dyes and protocols, and conditions that can raise staining independent of Sjögren's (for example, significant allergic eye disease, infection, or recent corneal trauma). Medications and contact lens use may also affect interpretation; testing should be performed in a way that reflects stable, representative disease activity when possible.
4. Schirmer test ≤5 mm in 5 minutes in at least one eye (1 point)
The Schirmer test (without topical anesthesia in the criteria methodology) provides a simple, widely available measure of tear secretion. A result of 5 mm or less wetting in 5 minutes in at least one eye satisfies the item.
Test performance is influenced by technique, patient cooperation, ambient humidity, concurrent ocular surface disease, and prior drops. Repeating abnormal results or combining with other objective measures strengthens confidence.
5. Unstimulated whole saliva flow ≤0.1 mL/min (1 point)
Whole-mouth, unstimulated salivary collection quantifies resting salivary hypofunction. The threshold is 0.1 mL/min or less, using the standardized collection approach specified for the criteria.
Many medications (anticholinergics, some antidepressants, antihistamines, and others) reduce measured flow. The original criteria note that patients on anticholinergic drugs should be evaluated for objective hypofunction after an adequate interval off these medications when feasible, so the measurement reflects underlying gland function rather than pharmacologic suppression alone.
How to compute the classification score
Sum the weights for each item that is clearly present:
| Item | Points if present |
|---|---|
| Labial salivary gland focal lymphocytic sialadenitis, focus score ≥1/4 mm² | 3 |
| Anti-SSA (Ro) positive | 3 |
| Ocular staining score ≥5 or van Bijsterveld score ≥4 (≥1 eye) | 1 |
| Schirmer ≤5 mm/5 min (≥1 eye) | 1 |
| Unstimulated whole saliva flow ≤0.1 mL/min | 1 |
The maximum possible total is 9. A total of ≥4 fulfills the 2016 ACR/EULAR classification definition of pSS when inclusion criteria are met and exclusion criteria are absent. Lower totals do not prove absence of treatable sicca or immune-mediated disease; they only indicate failure to meet this particular standardized case definition.
Common pitfalls in application
- Skipping inclusion/exclusion logic and reporting only a numeric score.
- Treating classification as diagnosis in medicolegal or treatment-mandating ways without clinical synthesis.
- Mixing incompatible test modifications (for example, Schirmer with anesthesia when the criterion specifies without, or non-standard saliva collection times).
- Ignoring drugs and comorbid ocular disease that can create false positives or false negatives on objective measures.
- Assuming negativity of one domain rules out disease; early or localized disease may not yet accumulate sufficient objective points even when symptoms are troublesome.
How this tool on CalcMD should be used
Use the calculator to tabulate the weighted total after you have verified inclusion, reviewed exclusions, and confirmed that each positive item truly meets the published thresholds and methods. Always interpret the result in the full clinical context, including medication effects, comorbidities, and the pretest probability of autoimmune exocrinopathy.